Eventide Asset Management Q2 2026 Portfolio Activity: Strategic Shifts in Biotech and Technology
Eventide Asset Management's portfolio saw significant changes during the second quarter of 2026, marked by substantial purchases in certain sectors and notable sales.
As reported for Eventide Asset Management (Eventide), this past quarter (ending June 30th) witnessed considerable activity across its holdings. The portfolio, valued at approximately $7.0 billion as of the reporting date, experienced a mix of buying and selling actions.
Notably, Eventide significantly increased its position in several companies during Q2. Key purchases included KLA Corporation (KLAC), where the holding saw an increase of over 750% (+299,614 shares). Another major buy was Dell Technologies Inc. (DELL). The investor also boosted its stake in IMMIX BioPharma Inc. (IMMX) by over 50% (+1,342,000 shares). Furthermore, positions were notably increased in CDNS Holdings Ltd. (CDNS), and there was a large purchase of MDB Inc. (MDB) shares.
In contrast, Eventide also made significant moves to sell or reduce positions during the quarter. The investor sold out entirely from APOGEE Therapeutics Inc. (APGE), reducing its allocation percentage significantly and eliminating it from the portfolio (-297,423 shares). There was also a substantial reduction in holdings of WellCare Health Pharmaceuticals Inc. (WCN) and exits reported for companies like Flex Ltd. (FLEX), CRWD Holdings Inc. (CRWD), and the previously mentioned APOGEE.
These changes reflect a dynamic investment strategy focused on capitalizing on specific opportunities while managing risk by exiting or reducing exposure in others. The portfolio's holdings count remains substantial at 280 stocks, indicating Eventide maintains a diverse set of investments.
The investor also demonstrated significant buying power during the quarter, acquiring large blocks of stock like KLA Corp and IMMIX BioPharma. Conversely, they showed capacity for large sales, as seen with the exit from Flex Ltd. (-297,423 shares) and other notable disposals.
Overall, Eventide's Q2 2026 activity involved substantial buying in select Technology and Healthcare stocks (including KLAC, IMMX) while simultaneously selling large positions or exiting holdings from other sectors. This indicates a focused approach on specific growth areas alongside strategic reductions elsewhere.